Adverum Biotechnologies Cash Flow from Operating Activities 2013-2025 | ADVM

Adverum Biotechnologies cash flow from operating activities from 2013 to 2025. Cash flow from operating activities can be defined as a company's cash flows from operations.

Adverum Biotechnologies Cash Flow from Operating Activities 2013-2025 | ADVM

Adverum Biotechnologies cash flow from operating activities from 2013 to 2025. Cash flow from operating activities can be defined as a company's cash flows from operations.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$247.1B
Amgen (AMGN)$155.3B
Gilead Sciences (GILD)$141.6B
Vertex Pharmaceuticals (VRTX)$99.7B
Bristol Myers Squibb (BMY)$96B
GSK (GSK)$80.7B
CSL (CSLLY)$67.1B
Regeneron Pharmaceuticals (REGN)$60.7B
Alnylam Pharmaceuticals (ALNY)$58.2B
Argenex SE (ARGX)$41.5B
Insmed (INSM)$27.1B
BioNTech SE (BNTX)$25.3B
Royalty Pharma (RPRX)$21B
Biogen (BIIB)$20B
Incyte (INCY)$16.6B
Genmab (GNMSF)$16.2B
Genmab (GMAB)$15.6B
Illumina (ILMN)$15.3B
Ascendis Pharma (ASND)$11.7B
BioMarin Pharmaceutical (BMRN)$11.2B
Swedish Orphan Biovitrum (BIOVF)$10.9B
QIAGEN (QGEN)$10.9B
Exelixis (EXEL)$10.2B
Moderna (MRNA)$9.9B
Verona Pharma American Depositary Share (VRNA)$9.1B
Bio-Techne Corp (TECH)$8.9B
Exact Sciences (EXAS)$8.6B
Halozyme Therapeutics (HALO)$8.4B
Blueprint Medicines (BPMC)$8.3B
Roivant Sciences (ROIV)$7.9B